Atlas Trials

MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)

Clinical trial NCT04841811 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04841811
Sponsor
Guangdong Association of Clinical Trials
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Lung Cancer
Start date
2022-06-20
Primary completion
2026-12-31
Enrollment
192

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.